These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 21659823)

  • 21. Vasodilating versus first-generation β-blockers for cardiovascular protection.
    Fares H; Lavie CJ; Ventura HO
    Postgrad Med; 2012 Mar; 124(2):7-15. PubMed ID: 22437211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stereochemical comparison of nebivolol with other beta-blockers.
    Siebert CD; Hänsicke A; Nagel T
    Chirality; 2008 Feb; 20(2):103-9. PubMed ID: 18072266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of nebivolol on the cardiovascular hemodynamics during postural changes and isometric exercise.
    Duprez D; Lefebvre R; De Backer T; De Sutter P; Trouerbach J; Clement DL
    Cardiovasc Drugs Ther; 1991 Aug; 5(4):709-17. PubMed ID: 1679662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Beta blocker improves the endothelial function. Gas-forming blood vessel protection].
    MMW Fortschr Med; 2003 Dec; 145(51-52):41. PubMed ID: 14974334
    [No Abstract]   [Full Text] [Related]  

  • 25. [Role of the L-arginine/nitric oxide system in the action of nebivolol].
    Brodde OE; Philipp T
    Dtsch Med Wochenschr; 2006 Nov; 131(45):2545-50. PubMed ID: 17091442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients.
    Pasini AF; Garbin U; Stranieri C; Boccioletti V; Mozzini C; Manfro S; Pasini A; Cominacini M; Cominacini L
    Am J Hypertens; 2008 Nov; 21(11):1251-7. PubMed ID: 18772860
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nebivolol: in the treatment of hypertension in the US.
    Baldwin CM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(4):253-60. PubMed ID: 19655820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nebivolol, atenolol and propranolol on in vivo cardiovascular and metabolic responses to isoproterenol in dogs.
    Bowden CR; Marchione CS
    J Pharmacol Exp Ther; 1989 Nov; 251(2):599-605. PubMed ID: 2572694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug approvals: '08 in review. Nebivolol (Bystolic).
    Laustsen G; Carrillo F; Johnson J; Smith C
    Nurse Pract; 2009 Feb; 34(2):25-6. PubMed ID: 19155877
    [No Abstract]   [Full Text] [Related]  

  • 30. Nebivolol (Bystolic) for hypertension.
    Med Lett Drugs Ther; 2008 Mar; 50(1281):17-9. PubMed ID: 18323772
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hemodynamic properties of nebivolol].
    Vecchione C; Fratta L; Rozza F; Trimarco G; Selvetella G; Guerrera L; Pilato G; Trimarco B
    Cardiologia; 1999 Dec; 44 Suppl 1(Pt 1):369-72. PubMed ID: 12497937
    [No Abstract]   [Full Text] [Related]  

  • 32. Nebivolol attenuates prooxidant and profibrotic mechanisms involving TGF-β and MMPs, and decreases vascular remodeling in renovascular hypertension.
    Ceron CS; Rizzi E; Guimarães DA; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2013 Dec; 65():47-56. PubMed ID: 23806385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between the sympatholytic action of nebivolol and hypotension.
    Ward JE; Coles P; Cox H; Eisenhofer G; Angus JA
    J Cardiovasc Pharmacol; 1992 Jul; 20(1):115-24. PubMed ID: 1383620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta-blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection.
    Mahmud A; Feely J
    Am J Hypertens; 2008 Jun; 21(6):663-7. PubMed ID: 18437130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age.
    Ladage D; Reidenbach C; Rieckeheer E; Graf C; Schwinger RH; Brixius K
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):275-81. PubMed ID: 20571428
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does nebivolol influence serum concentrations of proinflammatory cytokines in hypertensive (SHR) and normotensive (WKY) rats?
    Górska D; Dudarewicz M; Czarnecka E; Andrzejczak D
    Pharmacol Rep; 2010; 62(1):86-94. PubMed ID: 20360618
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension].
    MMW Fortschr Med; 2003 Oct; 145(40):57. PubMed ID: 14603611
    [No Abstract]   [Full Text] [Related]  

  • 38. Nebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.
    Prisant LM
    J Clin Pharmacol; 2008 Feb; 48(2):225-39. PubMed ID: 18083889
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An in-depth analysis of vasodilation in the management of hypertension: focus on adrenergic blockade.
    Bakris G
    J Cardiovasc Pharmacol; 2009 May; 53(5):379-87. PubMed ID: 19454898
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of nebivolol compared with other antihypertensive drugs: a meta-analysis.
    Van Bortel LM; Fici F; Mascagni F
    Am J Cardiovasc Drugs; 2008; 8(1):35-44. PubMed ID: 18303936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.